New HIV Frontier: The Fight To Access Long-Acting Prevention Drugs - Health Policy Watch

Last month, Médecins sans Frontières (MSF) launched a campaign to demand that the US-based Gilead “immediately make the highly effective HIV prevention

Brazilian Health Minister Dr Alexandre Padilha RIO DE JANEIRO – News that an antiretroviral drug injected twice a year had prevented almost all HIV infection in trials electrified the HIV sector two years ago – but access to Gilead’s lenacapavir has been slow, particularly for countries in Latin America. Brazil, which faces significant HIV transmission in certain groups, has been routinely excluded from HIV voluntary licensing deals offered by pharmaceutical companies – particularly for long-acting pre-exposure prophylaxis (PrEP) – as it is deemed an upper-middle-income country. Brazilian Heal

related reading

• Hard Drugs | Lenacapavir: The miracle drug that could end AIDSharddrugs.worksinprogress.co
• FDA approves lenacapavir as a twice-a-year shot to prevent HIV | AP Newsapnews.com
• Why we didn't get a malaria vaccine sooner - Works in Progress Magazineworksinprogress.co
• New HIV vaccine shows unprecedented success in preclinical study – lji.orglji.org
• HIV epidemic in the Philippines: The 2nd wave | Xtra Magazinextramagazine.com
• Exploring the barriers to the antiretroviral therapy adherence among people living with HIV in Bangladesh: A qualitative approachpmc.ncbi.nlm.nih.gov
• How To Save Twenty Million Lives, with Dr. Mark Dybulstatecraft.pub
• Zidovudine - Wikipediaen.wikipedia.org
• The Missing Tool in the Climate Fightssir.org
• Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexatencbi.nlm.nih.gov
• Grant for the support the development of MAP for self-administration of contraceptivesltslohmann.com
• Africa sets sights on innovative mRNA jab to help meet vaccine gapmedicalxpress.com